title: ACS chemical neuroscience molecule spotlight on RG1678.
abstract: RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.
authors.affiliation: Department of Pharmacology and Chemistry, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, USA.
authors.forename: Corey R
authors.initials: CR
authors.lastname: Hopkins
mesh_terms: D000818:Animals; D017326:Clinical Trials, Phase III as Topic / Q000639:trends; D050487:Glycine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D009488:Neurosciences; D010879:Piperazines / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism; D012958:Societies, Scientific; D013450:Sulfones / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: C550631:(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone; D050487:Glycine Plasma Membrane Transport Proteins; D010879:Piperazines; C493268:SLC6A9 protein, human; D013450:Sulfones